Clinical Trial Update: Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pacritinib to best available therapy in myelofibrosis with thrombocytopenia was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: CTI BioPharma | Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Status: TERMINATED | Results posted: 2021-11-18